Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (603896.SS)
CNY15.06
+0.57 (+3.93%)
CN SHH Healthcare Biotechnology
Address
No. 12, Huanglong Third Road 321200
Jinhua, CN
Jinhua, CN
CEO
Zhen-Yu Li
Website
sxg1909.com
IPO
2017-05-10
ISIN CNE100002XJ4
Description
Zhejiang Shouxiangu Pharmaceutical Co., Ltd., founded in 1997 and based in Jinhua, China, is dedicated to the investigation, creation, and commercialization of traditional Chinese medicine preparations. Their extensive product line features prominent items such as ganoderma lucidum spore powder, dendrobium officinale, and crocus sativus, among various other wellness-focused offerings.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY15.06
+0.57 (+3.93%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.24
Float Shares
194.64M
Free Float %
98.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.98% | -2.89% | -11.67% | -25.19% | -23.22% | -20.33% | -33.90% | -67.13% | -46.80% | +20.81% | +20.81% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
15.06
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.97
Grey zone
Piotroski F-Score
3 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-7.5% Q1'26: -5.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-89.8% Q1'26: -48.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+15.8% Q1'26: -16.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+19.7% ★ Q1'26: +17.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+4.4% ★ Q1'26: +6.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.7% ★ Q1'26: -1.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×2.73× ★ Q1'26: 4.94× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 2 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
369.96M
est: 364.83M (+1.4%)
|
511.45M
est: 433.41M (+18.0%)
|
546.76M
est: 660.00M (-17.2%)
|
636.05M
est: 546.95M (+16.3%)
|
767.14M
est: 767.00M (+0.0%)
|
829.07M
est: 829.00M (+0.0%)
|
784.35M
est: 765.44M (+2.5%)
|
691.68M
est: 860.00M (-19.6%)
|
640.18M
est: 756.71M (-15.4%)
|
656.00M
656.00M – 656.00M
-13.3% YoY
|
706.00M
706.00M – 706.00M
+7.6% YoY
|
759.00M
759.00M – 759.00M
+7.5% YoY
|
| EBITDA |
127.32M
est: 148.23M (-14.1%)
|
149.86M
est: 176.10M (-14.9%)
|
167.01M
est: 268.16M (-37.7%)
|
209.02M
est: 222.23M (-5.9%)
|
260.69M
est: 311.64M (-16.3%)
|
348.69M
est: 336.83M (+3.5%)
|
346.49M
est: 292.75M (+18.4%)
|
254.26M
est: 328.91M (-22.7%)
|
219.27M
est: 289.41M (-24.2%)
|
250.89M
250.89M – 250.89M
-13.3% YoY
|
270.01M
270.01M – 270.01M
+7.6% YoY
|
290.28M
290.28M – 290.28M
+7.5% YoY
|
| EBIT |
90.70M
est: 110.93M (-18.2%)
|
111.06M
est: 131.78M (-15.7%)
|
125.97M
est: 200.67M (-37.2%)
|
165.69M
est: 166.30M (-0.4%)
|
211.51M
est: 233.21M (-9.3%)
|
291.36M
est: 252.06M (+15.6%)
|
279.96M
est: 222.87M (+25.6%)
|
189.79M
est: 250.41M (-24.2%)
|
126.35M
est: 220.33M (-42.7%)
|
191.01M
191.01M – 191.01M
-13.3% YoY
|
205.57M
205.57M – 205.57M
+7.6% YoY
|
221.00M
221.00M – 221.00M
+7.5% YoY
|
| Net Income |
88.88M
est: 102.17M (-13.0%)
|
107.65M
est: 114.37M (-5.9%)
|
123.90M
est: 129.62M (-4.4%)
|
151.71M
est: 134.20M (+13.1%)
|
200.83M
est: 202.82M (-1.0%)
|
277.78M
est: 278.86M (-0.4%)
|
254.48M
est: 272.36M (-6.6%)
|
174.71M
est: 280.69M (-37.8%)
|
18.17M
est: 185.82M (-90.2%)
|
109.05M
104.52M – 113.57M
-41.3% YoY
|
139.34M
139.34M – 139.34M
+27.8% YoY
|
163.57M
163.57M – 163.57M
+17.4% YoY
|
| SGA |
208.73M
est: 162.38M (+28.5%)
|
300.56M
est: 192.90M (+55.8%)
|
305.78M
est: 293.75M (+4.1%)
|
329.97M
est: 243.44M (+35.5%)
|
390.89M
est: 341.38M (+14.5%)
|
399.57M
est: 368.97M (+8.3%)
|
396.78M
est: 368.11M (+7.8%)
|
383.01M
est: 413.59M (-7.4%)
|
226.29M
est: 363.91M (-37.8%)
|
315.48M
315.48M – 315.48M
-13.3% YoY
|
339.53M
339.53M – 339.53M
+7.6% YoY
|
365.01M
365.01M – 365.01M
+7.5% YoY
|
| EPS |
0.55
est: 0.52 (+6.7%)
|
0.58
est: 0.58 (+0.5%)
|
0.68
est: 0.65 (+4.0%)
|
0.82
est: 0.68 (+21.1%)
|
1.05
est: 1.02 (+2.6%)
|
1.43
est: 1.41 (+1.7%)
|
1.30
est: 1.35 (-3.6%)
|
0.88
est: 1.39 (-36.7%)
|
0.09
est: 0.92 (-90.2%)
|
0.54
0.52 – 0.56
-41.1% YoY
|
0.69
0.69 – 0.69
+27.8% YoY
|
0.81
0.81 – 0.81
+17.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-101.64M
OE per share TTM
-0.51
Owner's Yield
-3.32%
Maintenance CapEx ratio
231.02%
Maint CapEx / Avg PPE
89.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 2 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 30.0K | 0.29% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 5.5K | 0.39% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
113.0K
Shares Outstanding
198.24M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Biao Zhu | Financial Director | — | male |
| Guofang Liu | Deputy GM, Board Secretary & Director | — | female |
| Hai Feng Sun | Accounting Supervisor | — | — |
| Han Bo Wang | Deputy General Manager | — | male |
| Jing Xu | Deputy GM & Director | — | male |
| Rong Zhi Lin | VP & Director | — | male |
| Zhen-Yu Li | GM & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603896.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
